Clinical significance of apolipoprotein A5
- PMID: 18607181
- PMCID: PMC4428951
- DOI: 10.1097/MOL.0b013e328304b681
Clinical significance of apolipoprotein A5
Abstract
Purpose of review: We have examined the evidence from recent human studies examining the role of apolipoprotein A-V in triglyceride-rich lipoprotein metabolism and cardiovascular disease risk. Special emphasis was placed on the evidence emerging from the association between genetic variability at the apolipoprotein A5 locus, lipid phenotypes and disease outcomes. Moreover, we address recent reports evaluating apolipoprotein A5 gene-environment interactions in relation to cardiovascular disease and its common risk factors.
Recent findings: Several genetic association studies have continued to strengthen the position of APOA5 as a major gene that is involved in triglyceride metabolism and modulated by dietary factors and pharmacological therapies. Moreover, genetic variants at this locus have been significantly associated with both coronary disease and stroke risks.
Summary: Apolipoprotein A-V has an important role in lipid metabolism, specifically for triglyceride-rich lipoproteins. However, its mechanism of action is still poorly understood. Clinical significance at present comes largely from genetic studies showing a consistent association with plasma triglyceride concentrations. Moreover, the effects of common genetic variants on triglyceride concentrations and disease risk are further modulated by other factors such as diet, pharmacological interventions and BMI. Therefore, these genetic variants could be potentially used to predict cardiovascular disease risk and individualize therapeutic options to decrease cardiovascular disease risk.
Similar articles
-
The role of apolipoprotein A5 in obesity and the metabolic syndrome.Biol Rev Camb Philos Soc. 2013 May;88(2):490-8. doi: 10.1111/brv.12005. Epub 2012 Dec 22. Biol Rev Camb Philos Soc. 2013. PMID: 23279260 Review.
-
The paradox of ApoA5 modulation of triglycerides: evidence from clinical and basic research.Clin Biochem. 2013 Jan;46(1-2):12-9. doi: 10.1016/j.clinbiochem.2012.09.007. Epub 2012 Sep 19. Clin Biochem. 2013. PMID: 23000317 Free PMC article. Review.
-
Is apolipoprotein A5 a novel regulator of triglyceride-rich lipoproteins?Ann Med. 2006;38(1):2-10. doi: 10.1080/07853890500407488. Ann Med. 2006. PMID: 16448983 Review.
-
Common functional variants of APOA5 and GCKR accumulate gradually in association with triglyceride increase in metabolic syndrome patients.Mol Biol Rep. 2012 Feb;39(2):1949-55. doi: 10.1007/s11033-011-0942-8. Epub 2011 Jun 4. Mol Biol Rep. 2012. PMID: 21643755
-
[Impact of apolipoprotein A5 on cardiovascular risk. Genetic and environmental modulation].Rev Med Chil. 2010 Jul;138(7):868-80. doi: 10.4067/s0034-98872010000700013. Rev Med Chil. 2010. PMID: 21043084 Review. Spanish.
Cited by
-
Plasma Apolipoprotein A-V Predicts Long-term Survival in Chronic Hepatitis B Patients with Acute-on-Chronic Liver Failure.Sci Rep. 2017 Mar 30;7:45576. doi: 10.1038/srep45576. Sci Rep. 2017. PMID: 28358016 Free PMC article. Clinical Trial.
-
Apolipoprotein A5 polymorphisms interact with total dietary fat intake in association with markers of metabolic syndrome in Puerto Rican older adults.J Nutr. 2009 Dec;139(12):2301-8. doi: 10.3945/jn.109.109900. Epub 2009 Oct 14. J Nutr. 2009. PMID: 19828688 Free PMC article.
-
Structural and functional analysis of APOA5 mutations identified in patients with severe hypertriglyceridemia.J Lipid Res. 2013 Mar;54(3):649-661. doi: 10.1194/jlr.M031195. Epub 2013 Jan 10. J Lipid Res. 2013. PMID: 23307945 Free PMC article.
-
Apolipoprotein A5-1131T>C polymorphism, but not APOE genotypes, increases susceptibility for dyslipidemia in children and adolescents.Mol Biol Rep. 2011 Oct;38(7):4381-8. doi: 10.1007/s11033-010-0565-5. Epub 2010 Dec 4. Mol Biol Rep. 2011. PMID: 21132386
-
Xuezhikang contributes to greater triglyceride reduction than simvastatin in hypertriglyceridemia rats by up-regulating apolipoprotein A5 via the PPARα signaling pathway.PLoS One. 2017 Sep 21;12(9):e0184949. doi: 10.1371/journal.pone.0184949. eCollection 2017. PLoS One. 2017. PMID: 28934253 Free PMC article.
References
-
- Calandra S, Priore Oliva C, Tarugi P, Bertolini S. APOA5 and triglyceride metabolism, lesson from human APOA5 deficiency. Curr Opin Lipidol. 2006;17:122–127. - PubMed
-
- Ishihara M, Kujiraoka T, Iwasaki T, et al. A sandwich enzyme-linked immunosorbent assay for human plasma apolipoprotein A-V concentration. J Lipid Res. 2005;46:2015–2022. - PubMed
-
- Dallinga-Thie GM, van Tol A, Hattori H, et al. Plasma apolipoprotein A5 and triglycerides in type 2 diabetes. Diabetologia. 2006;49:1505–1511. - PubMed
-
- Henneman P, Schaap FG, Havekes LM, et al. Plasma apoAV levels are markedly elevated in severe hypertriglyceridemia and positively correlated with the APOA5 S19W polymorphism. Atherosclerosis. 2007;193:129–134. - PubMed
-
- Schaap FG, Nierman MC, Berbee JF, et al. Evidence for a complex relationship between apoA-V and apoC-III in patients with severe hypertriglyceridemia. J Lipid Res. 2006;47:2333–2339. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Molecular Biology Databases
Research Materials
Miscellaneous